Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (101-110 of 230) with videos related to

Pageof 23
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|May 11, 2015
Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostateFrank Giton, Nanor Sirab, Grégory Franck, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Urologia Internationalis|March 11, 2010
Extended biopsy protocol decreases prostate cancer incidence and risk of aggressive disease on repeated biopsies compared with initial standard procedureGuillaume Ploussard, Laurence Bastien, Aurélien Descazeaud, et al.
Journal of Endourology|May 29, 2009
Is robot assistance affecting operating room time compared with pure retroperitoneal laparoscopic radical prostatectomy?Guillaume Ploussard, Evanguelos Xylinas, Alexandre Paul, et al.
Cancer|February 3, 2015
Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancerStéphane Terry, Nathalie Nicolaiew, Victor Basset, et al.
The Journal of Urology|April 20, 2010
The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancerAndrea Guevara, Laurent Salomon, Yves Allory, et al.
Journal of Cellular and Molecular Medicine|June 29, 2021
Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancerTim Muilwijk, Murat Akand, Frank Van der Aa, et al.
Frontiers in Oncology|June 12, 2023
A new tumorgraft panel to accelerate precision medicine in prostate cancerClaire Béraud, Nadege Bidan, Myriam Lassalle, et al.
World Journal of Urology|November 8, 2006
Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimenAurélien Descazeaud, Mark Rubin, Stéphanie Chemama, et al.
Cancers|March 29, 2023
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Clémentine Krucker, et al.
Pageof 23

Showing results (101-110 of 230) with videos related to

Sort By:
Pageof 23
The Journal of Steroid Biochemistry and Molecular Biology|May 11, 2015
Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostateFrank Giton, Nanor Sirab, Grégory Franck, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Urologia Internationalis|March 11, 2010
Extended biopsy protocol decreases prostate cancer incidence and risk of aggressive disease on repeated biopsies compared with initial standard procedureGuillaume Ploussard, Laurence Bastien, Aurélien Descazeaud, et al.
Journal of Endourology|May 29, 2009
Is robot assistance affecting operating room time compared with pure retroperitoneal laparoscopic radical prostatectomy?Guillaume Ploussard, Evanguelos Xylinas, Alexandre Paul, et al.
Cancer|February 3, 2015
Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancerStéphane Terry, Nathalie Nicolaiew, Victor Basset, et al.
The Journal of Urology|April 20, 2010
The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancerAndrea Guevara, Laurent Salomon, Yves Allory, et al.
Journal of Cellular and Molecular Medicine|June 29, 2021
Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancerTim Muilwijk, Murat Akand, Frank Van der Aa, et al.
Frontiers in Oncology|June 12, 2023
A new tumorgraft panel to accelerate precision medicine in prostate cancerClaire Béraud, Nadege Bidan, Myriam Lassalle, et al.
World Journal of Urology|November 8, 2006
Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimenAurélien Descazeaud, Mark Rubin, Stéphanie Chemama, et al.
Cancers|March 29, 2023
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Clémentine Krucker, et al.
Pageof 23